By EnGeneIC
02 Uptake of payload Load potent chemotherapy, functional nucleic acids, or immune adjuvant in separate EDVs. 03 Attach antibody EDVs containing a potent chemotherapy payload have antibody attached to the nanocell wall. One arm of the antibody attaches to the nanocell, the other binds to the tumour via EGFR recognition (or any other chosen antigen). 04 Administration EDVs™ are IV infused over 5-10 mins. Targeted EDV™ with chemotherapy payload escape into the tumour microenvironment via leaky blood vessels caused by the tumour, to target cancer cells. Monitoring immune cells such as macrophages, dendritic cells and NK Cells take up EDVs and recognise bacterial origin of EDVs™. This stimulates fresh immune cells to be activated. 05 Targeted tumour killing EDVs containing potent chemotherapy payload are designed to bind to tumour cells via antibody (EGFR-directed), triggering engulfment and cell death. 06 Activate anti-tumour immune response EDVs activate an adaptive immune response by T Cells and iNKT Cells.
